In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invida Group Pte. Ltd.

Division of Menarini Group
www.invida.com

Latest From Invida Group Pte. Ltd.

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Roche Is Latest MNC To Partner A Primary Care Product In Korea

Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.

BioPharmaceutical South Korea

Deals Shaping The Medical Industry, June 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2011

Biopharmaceutical company financings more than doubled to $2.7 billion from Q3. There were 23 acquisitions bringing in a total of $17.7 billion. And in alliances there was a focus on biosimilars, oncology and neurology deals, and unique partnerships with clear paths to exits.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • Menarini Group
  • Senior Management
  • John Graham, CEO
    Anne M Bell, CFO
    Sumeet Sud, Chief Mktg. Officer
    Louis Payet, PhD, VP, Corp. Dev. & Alliance Mgt.
  • Contact Info
  • Invida Group Pte. Ltd.
    Phone: (65) 6494 7200
    79, Science Park Drive #05-01
    Cintech IV
    Science Park One, 118264
    Singapore
UsernamePublicRestriction

Register